Tag: executive

Retiring Chief Executive Officer Joe Adams Remains CEO of FS Bancorp until May 2026; Matt Mullet Named President and CEO of 1st Security Bank and will continue as President of FS Bancorp.

Oslo, Norway (15 August 2025) – TGS has issued awards of Performance Share Units (PSUs) and Restricted Share Units (RSUs) to 283 key employees of the Company, as authorized by the shareholders of the company at its Annual General Meeting on 8 May 2025.  With the exception of certain PSUs and RSUs, which may be secured by the Company’s treasury stock, the PSUs and RSUs are secured by free-standing warrants that, upon vesting of the PSUs and RSUs in accordance with their terms, are convertible to shares of the Company’s common stock.  Each PSU represents the right to receive a maximum of 1.5 shares, while each RSU represents the right to receive one share.

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Allied Properties REIT (“Allied”) (TSX:AP.UN) announced today that the Trustees of Allied have declared a distribution of $0.15 per unit for the month of August 2025, representing $1.80 per unit on an annualized basis. The distribution will be payable on September 15, 2025, to unitholders of record as at August 29, 2025.

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Fly-E Group, Inc. (Nasdaq: FLYE) (“Fly-E” or the “Company”), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, and electric scooters, today announced the grand opening of its newest retail location in Boston, Massachusetts. The new store, now fully operational, marks the Company’s continued expansion in the Northeastern United States and underscores its mission to make safe, reliable, and eco-friendly transportation accessible to more communities.

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

Shrisha Radhakrishna appointed as President and interim leader of Opendoor

Joins Workhorse’s proven vehicles, manufacturing capabilities and national dealer network with Motiv’s diverse product portfolio and top fleet relationships

Continued progress across pipeline programs with focus on pancreatic cancer